

1 **Title: Intrinsic growth rules of patients infected, dead and recovered with 2019**
2 **novel coronavirus in mainland China**

3 Chuanliang Han^{1△}, Yimeng Liu^{2,3,4△}, Saini Yang^{2,3,4*}

4
5 ¹State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern
6 Institute for Brain Research, Beijing Normal University, Beijing 100875, China

7 ²Key Laboratory of Environmental Change and Natural Disaster, Ministry of
8 Education, Beijing Normal University, Beijing 100875, China

9 ³State Key Laboratory of Earth Surface Processes and Resource Ecology, Beijing
10 Normal University, Beijing 100875, China

11 ⁴Academy of Disaster Reduction and Emergency Management Ministry of
12 Emergency Management and Ministry of Education, Faculty of Geographical Science,
13 Beijing Normal University, Beijing 100875, China

14
15 [△]C.L.H and Y.M.L contributed equally to this work

16
17 ***Correspondence authors:**

18 Saini Yang,
19 Key Laboratory of Environmental Change and Natural Disaster, Ministry of
20 Education & State Key Laboratory of Earth Surface Processes and Resource Ecology
21 & Academy of Disaster Reduction and Emergency Management Ministry of
22 Emergency Management and Ministry of Education, Faculty of Geographical Science,
23 Beijing Normal University, Beijing 100875, China

24 Email: yangsaini@bnu.edu.cn

25
26
27

28 **Abstract**

29 An outbreak of a novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19)
30 was first diagnosed in Wuhan, China, in December 2019 and then spread rapidly to
31 other regions. We collected the time series data of the cumulative number of
32 confirmed infected, dead, and cured cases from the health commissions in 31
33 provinces in mainland China. A descriptive model in a logistic form was formulated to
34 infer the intrinsic epidemic rules of COVID-19, which illustrates robustness spatially
35 and temporally. Our model is robust ($R^2>0.95$) to depict the intrinsic growth rule for
36 the cumulative number of confirmed infected, dead, and cured cases in 31 provinces
37 in mainland China. Furthermore, we compared the intrinsic epidemic rules of
38 COVID-19 in Hubei with that of severe acute respiratory syndrome (SARS) in
39 Beijing, which was obtained from the Ministry of Public Health of China in 2003. We
40 found that the infected case is the earliest to be saturated and has the lowest
41 semi-saturation period compared with deaths and cured cases for both COVID-19 and
42 SARS. All the three types of SARS cases are later to saturate and have longer
43 semi-saturation period than that of COVID-19. Despite the virus caused SARS
44 (SARS-CoV) and the virus caused COVID-19 (SARS-CoV-2) are homologous, the
45 duration of the outbreak would be shorter for COVID-19.

46

47 **Introduction**

48 In December 2019, a novel coronavirus-infected pneumonia causing human infection
49 was first identified in Wuhan, a city of Hubei province located in central China with a
50 population of 11 million people^{1,2}. The coronavirus was firstly named as 2019-nCoV
51 on January 12, 2020 and may have a probable bat origin³. Human to human
52 transmission through 2019-nCoV has been confirmed among closed contacts since the
53 middle of December 2019^{4,5}. As of February 29, 2020, infections of 2019-nCoV have
54 been identified in all Chinese provincial administrative regions and in dozens of
55 countries around the world⁶⁻¹⁰. There have been a total of 79824 confirmed cases of
56 2019-nCoV infections in mainland China, including 2870 deaths and 41625 cases
57 cured¹¹. So far, the coronavirus has been renamed as COVID-19 on February 12, 2020
58 officially. Different from a previous famous beta coronavirus in 2003, severe acute
59 respiratory syndrome coronavirus (SARS-CoV)¹²⁻¹⁴ that has a mortality rates of 10%¹⁵,
60 that of COVID-19 is 4.13% in Hubei province, and 0.84% in rest of mainland China¹¹
61 up to February 29, 2020.

62

63 Here, we used a descriptive model to fit data on the 2019-nCoV cases (infection, death,
64 cure) from January 20, 2020 to February 29, 2020, aiming to capture the
65 epidemiologic characteristics and dynamics of COVID-19 in 31 provinces in
66 mainland China. Furthermore, we compared these characteristics with SARS in 2003
67 using the same model structure in order to validate this model and understand the
68 differences among these two diseases.

69

70 **Results**

71 **Intrinsic growth rules of COVID-19 infections in mainland China**

72 Hubei province contributed a majority of infections to this statistical numbers (Fig
73 1A). Based on the cumulative infected case data of COVID-19, we firstly established
74 a descriptive model with three parameters for each of the 31 provinces in mainland
75 China (Fig 1B & Fig 2B, See Methods). Fitting goodness of models was expressed by
76 the R-square, which ranged from 0.95 to 0.999, indicating that the models we
77 established fitted the data well. The panel B of Figure 1 illustrates examples of time
78 series data of infected cases and corresponding fitting curves in five provinces
79 (provinces of Xinjiang, Beijing, Guangdong, Zhejiang and Heilongjiang) and that of
80 all provinces can be found in Supplementary Figure S1. It is clear that different
81 province varied in patterns of increase of infected cases (Fig 1B).

82

83 In our model, parameter k is an important parameter to depict the intrinsic growth rule
84 of cumulative number of infected patients (Equation (8)). We assume that the growth
85 pattern follows a sigmoid form, and the parameter k here denotes how rapid the
86 number of infected cases get to saturate. If k is large, the S form of the curve would be
87 sharp, and the curve will rise up very quickly to be saturated to the maximum number.
88 While if k is only slightly larger than 0, the curve would show a slow and smooth
89 increase from 0 to the maximum.

90

91 To further illustrate the spatial distribution of the infected cases' growth pattern, we
92 exerted further analyses of the fitted infected case curves of 30 provinces. We
93 excluded Tibet in this analysis because the number of confirmed infected case did not
94 increase since Jan 29, 2020. The only one confirmed case in Tibet has been cured on
95 Feb 12. The spatial distribution of parameter k is shown in Fig 2A, illustrating
96 provinces varied in the increase patterns of cumulative infected cases. Fitted curves of
97 provinces such as Jilin and Qinghai has larger value of k , which means that the

98 number of infections peaked earlier in these regions than in other provinces. By
99 contrast, provinces like Hainan, Hebei, Ningxia, has smaller value of k than other
100 provinces, suggesting the infections of these provinces would continue increasing
101 when infections of other provinces reach saturation (Fig 2B). Fig 2C shows the spatial
102 distribution of predicted maximum number of infected cases (parameter A) in each
103 province of mainland China. With the data up to Feb. 29th, our model shows that the
104 maximum number of infected COVID-19 cases in mainland China would be 80119
105 (95% confidence interval: [79133, 81105]). Among all the provinces in mainland
106 China, the Hubei province is predicted to have largest number of infected COVID-19
107 cases, which would be 66750 (95% confidence interval: [65939,67561]).

108

109 Our model could not only well explain the data in various geographic space, but also
110 provided robust results with different length of time series (Fig 2D-F). We used our
111 model to fit the data by Feb 19 and Feb 29 respectively, and the parameters estimated
112 by the two dataset do not have significant difference (for k , $t=0.09$, $p=0.93$; for t_0 ,
113 $t=0.04$, $p=0.97$; for A , $t=0.02$, $p=0.98$; two-tailed test). This model's spatial and
114 temporal robustness provides us confidence in further analyses.

115

116 **Comparison of intrinsic epidemic rules between COVID-19 in Wuhan and SARS** 117 **in Beijing (2003)**

118 To compare the intrinsic growth rule of infected cases, dead cases and cured cases
119 between COVID-19 and SARS, we applied the descriptive model to fit the data of
120 SARS in Beijing 2003 (Fig 3A). Since the time series data of SARS was full phase of
121 the outbreak, the parameters estimated by our model was solid ($R\text{-square}>0.95$). We
122 found the k value of fitted curves of infected SARS cases in Beijing was 0.18, which
123 was much lower than that of COVID-19 ($k = 0.25$) in Hubei Province (Fig 3 ABC).
124 Furthermore, we found that all 30 provinces' k values were significantly larger than
125 0.18 ($t=10.71$, $p<0.0001$, right-tailed test) (Fig 3D). We also noted the t_0 of fitted

126 curves of infected SARS cases in Beijing was larger than that of fitted curves of
127 infected COVID-19 cases in all provinces (Fig 3E). Moreover, the increasing rate (k)
128 was negatively correlated (Pearson, $r = -0.44$, $p = 0.0125$) to semi-saturation period
129 (Fig 3F). We concluded that at the provincial level, the COVID-19 spread more
130 quickly than the SARS did. The infections of COVID-19 increased more rapid and
131 would reach saturation earlier than SARS according to our model.

132

133 **Intrinsic rules of infection, death and recovery of COVID-19 and SARS2003**

134 The outbreak of SARS in Beijing was the most serious among all the provincial
135 administrative regions, and the outbreak of COVID-19 was most serious in Hubei
136 province. Here we used our descriptive model to fit the dead and cured cases' curves
137 for SARS in Beijing and COVID-19 in Hubei province (Fig 4 A-C, F-H, $R\text{-square} \geq$
138 0.95, for other provinces in mainland China, see Fig S2, S3), and compared the
139 growth features of three types cases of SARS and COVID-19 by two parameters, k
140 and t_0 (Fig 4 DEIJ). We found that k values of the three types cases of SARS were
141 lower than that of COVID-19 (Fig 4 DE), and semi-saturation period for them in
142 SARS was higher than COVID-19's, which suggested the duration of COVID-19
143 would be shorter than that of SARS. For both SARS and COVID-19, their infected
144 curves have the lowest semi-saturation period (Fig 4 EJ), while cured curves have the
145 highest which is in keeping with the common sense that the cure is always later than
146 infection and death. For both SARS in Beijing and COVID-19 in Hubei, the k values
147 of death case curves were lowest compared with curves of infected cases and cured
148 cases. For both SARS and COVID-19, the k value of infected case curve was larger
149 than that of cured curve.

150

151

152 **Discussion**

153 We modeled the epidemiologic characteristics of 2019-nCoV for 31 provinces in
154 mainland China based on the data from Jan 10 to Feb 29 during the outbreak (Hubei
155 province reported laboratory confirmed 2019-nCoV cases since Jan 10, while other
156 provinces in mainland China reported laboratory confirmed 2019-nCoV cases since
157 Jan 20). Furthermore, we compared these characteristics with SARS in 2003 using the
158 same model framework.

159

160 Compared with dynamical models such as SIR (Susceptible - Infectious - Recovered)
161 or SEIR (Susceptible - Exposed - Infectious - Recovered), our model is relatively
162 simple but robust. We used a differential equation in logistic form to describe the
163 dynamics of the infected, dead and healed cases caused by COVID-19 respectively
164 (See Methods). The increasing of the population no matter in which type of case
165 (infection, death or recovery) has multiple reasons. When the outbreak of COVID-19
166 originated in Wuhan, it did not cause too much concern at the beginning so that it
167 leads to many infections and starts to export potential exposed cases to other
168 provinces. But as the successive closure of the cities in Hubei province, and isolation
169 of the community in all the provinces in mainland China, the virus spread tendency
170 was weakened. In our model, we also considered these measures taken by the
171 government. We rewrote Equation (1) to Equation (9).

$$172 \quad \frac{dI(t)}{dt} = \alpha I(t) - rI^2(t) \quad (9)$$

173 where α is growth rate of the number of infections; $I(t)$ is cumulative number of
174 infections at time t ; r is a parameter to reflect the effect of measures aiming at
175 controlling the virus spread. Here we decompose $I(t)$ into two parts. The first part
176 $\alpha I(t)$ represents the rapid infections growth in the early phase of the outbreak
177 without any measures for epidemic control. The second part $rI^2(t)$ illustrates the
178 slower infections growth after taking effective isolation measures for epidemic control.
179 For death cases, this idea still holds. But things are different for cured case. In contrast,

180 at the early phase of the outbreak, the number of cured cases increase slowly. But
181 once there are effective treatments, the number of cured cases will rise up quickly.
182 The growth of cured cases would again be slow since the number of patients is limited.
183 All these facts were considered in our highly summarized model (Equation (8)) in a
184 macroscopic scale. Each fitted model has a R -square value greater than 0.95 to the
185 original data set, so that we could further discuss some intrinsic mechanisms for the
186 growth rules of infection, death and recovery through the parameters estimated from
187 this model (See Methods).

188

189 The value of k from Equation (8) is a critical parameter. k represents how rapid the
190 number of infected cases get to the saturation. We found the variability of k values
191 among fitted curves of infected COVID-19 cases in 30 provinces (exclude Tibet) (Fig
192 2 AB) is large (Ranging from 0.19 to 0.38). It is clear to show the real situation in
193 each province and this guides us to be more careful against the epidemic. Further we
194 compared this characteristics between COVID-19 and SARS in 2003 in typical
195 provinces (Fig 3 AB). We noted that k values of fitted COVID-19 infection curves in
196 30 provinces of mainland China (exclude Tibet) are larger than that of SARS in
197 Beijing 2003 (Fig 3 C), which suggests the time cost of this epidemic will be shorter
198 compared with SARS in 2003. This result may relate to several aspects. Firstly, it may
199 due to the basic spread property of the virus. Besides, the isolation policy of all the
200 provinces in mainland China was more strictly enforced than it was in 2003.
201 Moreover, the improved clinical skills today may also helpful for shortening the
202 duration of epidemic.

203

204 Furthermore, we analyzed semi-saturation period (Fig 4 EK) (t_0 in Equation (8)) and
205 make comparison in three types of cases (infection, death and recovery) (Fig 4 A-C
206 G-I). k values for the fitted curves of the three types of cases caused by COVID-19
207 were larger than that of SARS, while t_0 values were the opposite. This again suggests

208 that the epidemic of COVID-19 will be quicker to pass away than SARS. For both
209 SARS and COVID-19, fitted curves of infections have lowest semi-saturation period
210 (Fig 4 EK), while fitted curves of cured cases have the highest semi-saturation period,
211 which follows the common sense that the cure was always later than infection and
212 death since it costs time to get on the research of effect plans to cure the patients. For
213 both SARS and COVID-19, the k value of infected case curve was larger than that of
214 cured curve, while that of death case is the lowest.

215

216 **Methods**

217 **Sources of data**

218 We obtained the time series data of 2019-nCoV cases from the National Health
219 Commission of China, and the provincial Health Commission of 31 provincial
220 administrative regions in mainland China (January 10 to February 29, 2020). The data
221 used in this study include the number of confirmed 2019-nCoV cases, the cumulative
222 number of suspected, dead, and cured cases. The 200 infected cases found in jail of
223 Shandong Province on Feb 20 were not counted in. All cases were laboratory
224 confirmed following the case definition by national health commission of China¹⁶.
225 The basic test procedure has been described in detail in previous work^{4,17}.

226

227 The severe acute respiratory syndrome (SARS) in 2003 was another fatal coronavirus
228 epidemics over the last two decades, we collected the data (the cumulative number of
229 suspected, dead, and cured cases) of SARS during March 1 to August 16, 2003, in
230 Beijing from the National Health and Family Planning Commission of PRC.

231

232 **Epidemic curve modeling**

233 We assumed the number of susceptible people per unit time was proportional to the
234 number of uninfected persons, and isolation or closure of the city could affect the
235 spread effect of infected to susceptible people to a certain extent. Previous studies

236 have showed that daily cumulative number of patients could be explained by logistic
237 function^{18,19}. Based on the above assumption and existing findings, we modeled the
238 epidemic information of virus as logistic form (Equation (1))

$$239 \quad \begin{cases} \frac{dI(t)}{dt} = \alpha I(t) \left(1 - \frac{I(t)}{N_1}\right) \\ I(0) = I_0 \end{cases} \quad (1)$$

240 where N_1 is maximum number of cumulative infections, $I(t)$ is cumulative number of
241 patients at time t , α is the incidence growth rate, and I_0 is the number of infected
242 cases at the initial time.

243 Analytical solution of Equation (1) could be written in the form of Equation (2)

$$244 \quad I(t) = \frac{N_1}{1 + C_1 e^{-\alpha t}} \quad (2)$$

$$245 \quad C_1 = \frac{N_1}{I_0} - 1 \quad (3)$$

246 Similarly, we could write the analytical solutions for the dead and cured cases by
247 Equation (4) and Equation (6).

$$248 \quad D(t) = \frac{N_2}{1 + C_2 e^{-\beta t}} \quad (4)$$

$$249 \quad C_2 = \left(\frac{N_2}{D_0} - 1\right) \quad (5)$$

$$250 \quad R(t) = \frac{N_3}{1 + C_3 e^{-\gamma t}} \quad (6)$$

$$251 \quad C_3 = \left(\frac{N_3}{R_0} - 1\right) \quad (7)$$

252 Where β , γ is the growth rate of dead cases and the growth rate of cured cases,
253 respectively. N_2 and N_3 is maximum number of cumulative dead and cured cases. D_0
254 and R_0 is the number of dead and cured cases at initial time.

255 Here we simplified Equation (2),(4),(6) and unified them as Equation (8)

$$256 \quad N(t) = \frac{A}{1 + e^{-k(t-t_0)}} \quad (8)$$

257 where $N(t)$ is the general form of $I(t)$, $D(t)$ or $R(t)$, A denotes N_1 , N_2 , or N_3 , and k
258 represents α , β , or γ , indicating the intrinsic rule for growth of cases. t_0 represents
259 the semi-saturation period, illustrating the inflection point of the sigmoid curve.

260

261 The data processing and modeling were performed on MATLAB (The MathWorks)
262 with custom scripts. The nonlinear least square (NLS) algorithm was adopted for data
263 fitting and parameter estimation. We used the MATLAB function “nlinfit” to
264 minimize the sum of squared differences between the data points and the fitted values.
265 Equation (8) was used in this work as the descriptive model to depict the intrinsic
266 growth rule for infected, dead and cured cases.

267

268

269

270 **References:**

- 271 1 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China,
272 2019. *N Engl J Med* **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 273 2 Hui, D. S. *et al.* The continuing 2019-nCoV epidemic threat of novel
274 coronaviruses to global health - The latest 2019 novel coronavirus outbreak in
275 Wuhan, China. *Int J Infect Dis* **91**, 264-266, doi:10.1016/j.ijid.2020.01.009
276 (2020).
- 277 3 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of
278 probable bat origin. *Nature*, doi:10.1038/s41586-020-2012-7 (2020).
- 279 4 Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel
280 Coronavirus-Infected Pneumonia. *N Engl J Med*,
281 doi:10.1056/NEJMoa2001316 (2020).
- 282 5 Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients With
283 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*,
284 doi:10.1001/jama.2020.1585 (2020).
- 285 6 Holshue, M. L. *et al.* First Case of 2019 Novel Coronavirus in the United
286 States. *N Engl J Med*, doi:10.1056/NEJMoa2001191 (2020).
- 287 7 Ki, M. & nCo, V. T. Epidemiologic characteristics of early cases with 2019
288 novel coronavirus (2019-nCoV) disease in Republic of Korea. *Epidemiol
289 Health*, e2020007, doi:10.4178/epih.e2020007 (2020).
- 290 8 Shigemura, J., Ursano, R. J., Morganstein, J. C., Kurosawa, M. & Benedek, D.
291 M. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan:
292 Mental health consequences and target populations. *Psychiatry Clin Neurosci*,
293 doi:10.1111/pcn.12988 (2020).
- 294 9 Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. & de Wit, E.
295 A Novel Coronavirus Emerging in China - Key Questions for Impact
296 Assessment. *N Engl J Med* **382**, 692-694, doi:10.1056/NEJMp2000929
297 (2020).
- 298 10 Nishiura, H. *et al.* The Rate of Underascertainment of Novel Coronavirus
299 (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on
300 Evacuation Flights. *J Clin Med* **9**, doi:10.3390/jcm9020419 (2020).
- 301 11 Prevention, C. C. f. D. C. a. *The latest situation of COVID-19*,
302 <[http://www.nhc.gov.cn/xcs/yqtb/202003/9d462194284840ad96ce75eb8e4c8](http://www.nhc.gov.cn/xcs/yqtb/202003/9d462194284840ad96ce75eb8e4c8039.shtml)
303 [039.shtml](http://www.nhc.gov.cn/xcs/yqtb/202003/9d462194284840ad96ce75eb8e4c8039.shtml)> (2020).
- 304 12 Drosten, C. *et al.* Identification of a novel coronavirus in patients with severe
305 acute respiratory syndrome. *New Engl J Med* **348**, 1967-1976, doi:DOI
306 10.1056/NEJMoa030747 (2003).
- 307 13 Ksiazek, T. G. *et al.* A novel coronavirus associated with severe acute
308 respiratory syndrome. *N Engl J Med* **348**, 1953-1966,
309 doi:10.1056/NEJMoa030781 (2003).
- 310 14 Kuiken, T. *et al.* Newly discovered coronavirus as the primary cause of severe
311 acute respiratory syndrome. *Lancet* **362**, 263-270, doi:Doi

- 312 10.1016/S0140-6736(03)13967-0 (2003).
- 313 15 WHO. *Summary of probable SARS cases with onset of illness from 1*
314 *November 2002 to 31 July 2003*,
315 [<https://www.who.int/csr/sars/country/table2004_04_21/en/>](https://www.who.int/csr/sars/country/table2004_04_21/en/) (2003).
- 316 16 Prevention, C. C. f. D. C. a. *Prevention and control measures of COVID-19*,
317 [http://www.nhc.gov.cn/jkj/s3577/202002/a5d6f7b8c48c451c87dba14889b30](http://www.nhc.gov.cn/jkj/s3577/202002/a5d6f7b8c48c451c87dba14889b30147/files/3514cb996ae24e2faf65953b4ecd0df4.pdf)
318 [147/files/3514cb996ae24e2faf65953b4ecd0df4.pdf](http://www.nhc.gov.cn/jkj/s3577/202002/a5d6f7b8c48c451c87dba14889b30147/files/3514cb996ae24e2faf65953b4ecd0df4.pdf)> (2020).
- 319 17 Huang, C. *et al.* Clinical features of patients infected with 2019 novel
320 coronavirus in Wuhan, China. *Lancet* **395**, 497-506,
321 doi:10.1016/S0140-6736(20)30183-5 (2020).
- 322 18 Huang, D., Guan, P. & Zhou, B. Fitness of morbidity and discussion of
323 epidemic characteristics of SARS based on logistic models. *Chinese Journal*
324 *of Public Health* **19**, 1-2 (2003).
- 325 19 Wang, Y. & Liu, x. The compound Logistic model used to describe epidemic
326 situation dynamics of SARS in Beijing. *Journal of China Jiliang University*
327 **16**, 159-162 (2005).

328

329 **ADDITIONAL INFORMATION**

330

331 **Acknowledgements:**

332 This study is sponsored by the National Key Research and Development Program of
333 China (2018YFC1508903), the National Natural Science Foundation of China
334 (41621061) and the support of International Center for Collaborative Research on
335 Disaster Risk Reduction (ICCR-DRR).

336

337

338 **Contributions:**

339 C.L.H, Y.M.L and S.N.Y designed the research. C.L.H and Y.M.L performed the
340 research. C.L.H and Y.M.L. analyzed the data. Y.M.L, C.L.H and S.N.Y wrote the
341 paper.

342

343

344 **Corresponding author:**

345 Correspondence to Yang Saini.

346 Email: yangsaini@bnu.edu.cn

347


348 **Competing interests**

349 The authors declare no competing interests.

350

351 |

352



353 **Figure 1 Spatial distribution**
354 **of the number of COVID-19**
355 **infected cases in mainland**
356 **China.**

357 Panel A is the spatial distribution of
358 the number of COVID-19 infected
359 cases of provinces in mainland
360 China.


361 Panel B takes five provinces
362 (Xinjiang, Beijing, Guangdong,
363 Zhejiang and Heilongjiang) as

364 example to show the time series of infected cases and corresponding fitted curve. The
365 horizontal axis is the x_{th} day after Jan 1, 2020. And the vertical axis denotes the
366 number of infected cases in corresponding province. The black dots in each panel are
367 raw data of the cumulative infected cases. The red line is the fitted curve by our
368 descriptive model. The dashed red lines show the 95% confidence interval of the
369 fitted curves.

370

371

372



373

374 **Fig 2 Spatial distribution of model parameters and robustness of the**
 375 **model**

376 Panel A demonstrates the spatial distribution of parameter k of provinces in mainland
 377 China (exclude Tibet, same for B-F).

378 Panel B shows the fitted curves of infected cases in 30 provinces (exclude Tibet). The
 379 vertical axis is the number of infected cases (normalized by dividing the maximum
 380 number of infected cases in each province). The color of each province is consistent
 381 with Panel A.

382 Panel C is the spatial distribution of the predicted maximum number (parameter A in
 383 our model) of COVID-19 infected cases of provinces in mainland China.

384 Panel D-F show the difference of parameters estimated from long (by the end of Feb
 385 29) and short (by the end of Feb 19) time series data, each dot denotes for one
 386 province.

387




Fig 3 Comparison of intrinsic epidemic rules between COVID-19 in Wuhan and SARS in Beijing (2003)

Panel A shows the raw data and fitted curve of SARS cases in Beijing. The horizontal axis is the x_{th} day after March 1, 2003. The vertical axis denotes the cumulative number of SARS cases in Beijing. The black dots are the raw data of the SARS cases. The red line is the fitted curve by our descriptive model. The dashed red lines are the 95% confidence interval of the fitted curves.


Panel B shows the raw data and fitted curve of COVID-19 cases in Hubei province. The horizontal axis is the x_{th} day after Jan 1, 2020. The vertical axis denotes the cumulative number of COVID-19 cases in Hubei. The black dots are raw data of the COVID-19 cases. The red line is the fitted curve by our descriptive model. The dashed red lines are the 95% confidence interval of the fitted curves.

413 Panel C shows the fitted curves of infected SARS cases (gray curve) and COVID-19
 414 (black curve), which are normalized by dividing the maximum number of infected
 415 cases in each province.
 416

417 Panel D illustrates the k value (increasing rate of infected cases) of fitted curves of
 418 infected COVID-19 cases in each province in mainland China, where Hubei is
 419 represented by the solid red square (the same in D and E). k value of fitted curves of
 420 infected SARS cases in Beijing is represented by the solid red triangle (the same in D
 421 and E).
 422

423 Panel E illustrates the t_0 (semi-saturation period) of fitted curves of infected
 424 COVID-19 cases in each province in mainland China, as well as t_0 of fitted curves of
 425 infected SARS cases in Beijing.
 426

427 The scatter plot of k and t_0 is shown in Panel F, indicating significant negative
 428 correlation between k and t_0 .
 429



430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450


Fig 4 Intrinsic rules of infection, death and recovery of COVID-19 and SARS2003

Panel A-C show the raw data and fitted curve of SARS cases in Beijing. Their horizontal axes are the x_{th} day after Mar 1, 2003. The black dots in Panel A, B and C are raw data of the SARS infected cases, dead cases and cured cases, respectively. The red lines are the fitted curves by our descriptive model. The dashed red lines are the 95% confidence interval of the fitted curves.

Panel D and Panel E respectively shows the k value and the t_0 of fitted curves of three types cases caused by SARS (the circle, triangle and square denotes infected, dead and cured cases, respectively, and the same in Panel I and J). The error bars show the 95% confidence interval of the parameters.

Panel F-H show the raw data and fitted curve of COVID-19 cases in Hubei. Their horizontal axes are the x_{th} day after Jan 1, 2020. The black dots in Panel F, G and H are raw data of the COVID-19 infected cases, dead cases and cured cases, respectively. The red lines are the fitted curves by our descriptive model. The dashed red lines are the 95% confidence interval of the fitted curves.


Panel I and Panel J respectively shows the k value and the t_0 of fitted curves of three types cases caused by COVID-19, which is same with D and E.



451
452
453
454
455
456

Supplement Figure S1 Intrinsic growth rules of patients infected with 2019 novel coronavirus in all provinces of mainland China


The black dots in each panel are raw data of the cumulative infected cases. The red line is the fitted curve by our descriptive model.



457
458
459
460
461
462

Supplement Figure S2 Intrinsic growth rules of patients dead with 2019 novel coronavirus in all provinces of mainland China (Excluded 0 death case provinces)

The black dots in each panel are raw data of the cumulative dead cases. The red line is the fitted curve by our descriptive model.



463
464
465
466
467
468
469
470
471

Supplement Figure S3 Intrinsic growth rules of patients cured with 2019 novel coronavirus in all provinces of mainland China

The black dots in each panel are raw data of the cumulative cured cases. The red line is the fitted curve by our descriptive model.